News Category: Earnings

– 1Q23 NUPLAZID ® net sales of $118.5 million – Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older on March 10, 2023 – Announced DAYBUE Availability on April 17, 2023 SAN DIEGO –(BUSINESS WIRE)–May

– Full year 2022 net sales of $517.2 million , an increase of 7% over 2021 – Prescription Drug User Fee Act (PDUFA) action date set for March 12, 2023 , for trofinetide for the treatment of Rett syndrome SAN DIEGO –(BUSINESS WIRE)–Feb. 27, 2023– Acadia Pharmaceuticals Inc.

– 3Q22 net sales of $130.7 million – Prescription Drug User Fee Act action date set for March 12, 2023   for trofinetide for the treatment of Rett syndrome SAN DIEGO –(BUSINESS WIRE)–Nov. 2, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third

– 2Q22 net sales of $134.6 million , a 17% increase over 2Q21 – NDA submitted for trofinetide for the treatment of Rett syndrome SAN DIEGO –(BUSINESS WIRE)–Aug. 8, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022 .

– 1Q22 net sales of $115.5 million , an 8% increase over 1Q21 – Reiterating FY22 net sales guidance of $510 to $560 million – FDA Advisory Committee meeting to review sNDA for pimavanserin for the treatment of ADP scheduled for June 17, 2022 SAN DIEGO –(BUSINESS WIRE)–May 4, 2022– Acadia

SAN DIEGO –(BUSINESS WIRE)–Apr. 18, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from a Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery.

– Full year 2021 net sales grew to $484.1 million , a 10% increase over 2020 – Resubmitted sNDA for pimavanserin for the treatment of Alzheimer’s disease psychosis – Delivered positive top-line results from the pivotal Phase 3 Lavender trial evaluating trofinetide for the treatment of Rett syndrome

– Trofinetide met co-primary efficacy endpoints demonstrating statistically significant improvement over placebo in the Rett Syndrome Behaviour Questionnaire (RSBQ) (p=0.0175) and the Clinical Global Impression of Improvement (CGI-I) (p=0.0030) – Trofinetide met key secondary endpoint demonstrating

– 3Q21 net sales of $131.6 million , a 9% increase over 3Q20 – FDA meeting scheduled to discuss next steps towards a resubmission of the pimavanserin sNDA SAN DIEGO –(BUSINESS WIRE)–Nov. 8, 2021– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third

– 2Q21 net sales of $115.2 million , a 5% increase over 2Q20 – Fiscal year 2021 revenue guidance reduced to $480 to $515 million   – Type A meeting held with FDA regarding DRP; Acadia will continue discussion with FDA in another meeting later this year SAN DIEGO –(BUSINESS WIRE)–Aug.